| (R)-adrenaline | increases expression | EXP | | 6480464 | Epinephrine results in increased expression of CTSK mRNA | CTD | PMID:12729923 |
| (S)-amphetamine | decreases expression | ISO | RGD:61810 | 6480464 | Dextroamphetamine results in decreased expression of CTSK mRNA | CTD | PMID:16715494 |
| 1,2,4-trimethylbenzene | decreases expression | ISO | RGD:61810 | 6480464 | pseudocumene results in decreased expression of CTSK protein | CTD | PMID:17337753 |
| 17alpha-ethynylestradiol | affects expression | ISO | RGD:61810 | 6480464 | Ethinyl Estradiol affects the expression of CTSK mRNA | CTD | PMID:17351261 |
| 17alpha-ethynylestradiol | increases expression | ISO | RGD:61810 | 6480464 | Ethinyl Estradiol results in increased expression of CTSK mRNA | CTD | PMID:12655037 |
| 17beta-estradiol | affects expression | ISO | RGD:62102 | 6480464 | Estradiol affects the expression of CTSK mRNA | CTD | PMID:17166402 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:62102 | 6480464 | Tetrachlorodibenzodioxin inhibits the reaction [tributyltin results in decreased expression of CTSK mRNA] | CTD | PMID:22749964 |
| 3,4-methylenedioxymethamphetamine | increases expression | ISO | RGD:62102 | 6480464 | N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of CTSK mRNA | CTD | PMID:20188158 |
| all-trans-retinoic acid | decreases expression | ISO | RGD:62102 | 6480464 | Tretinoin results in decreased expression of CTSK mRNA | CTD | PMID:18703560 |
| aluminium oxide | increases expression | EXP | | 6480464 | Aluminum Oxide results in increased expression of CTSK mRNA | CTD | PMID:19464052 |
| ammonium chloride | affects expression | ISO | RGD:61810 | 6480464 | Ammonium Chloride affects the expression of CTSK mRNA | CTD | PMID:16483693 |
| arsenic atom | increases expression | ISO | RGD:61810 | 6480464 | Arsenic results in increased expression of CTSK mRNA | CTD | PMID:18315880 |
| benzo[a]pyrene | affects expression | ISO | RGD:62102 | 6480464 | Benzo(a)pyrene affects the expression of CTSK mRNA | CTD | PMID:22342234 |
| beta-cryptoxanthin | multiple interactions | ISO | RGD:62102 | 6480464 | cryptoxanthin promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA]; more ... | CTD | PMID:18636177 |
| C60 fullerene | increases expression | ISO | RGD:61810 | 6480464 | fullerene C60 results in increased expression of CTSK mRNA | CTD | PMID:20471445 |
| chlorpromazine | multiple interactions | ISO | RGD:62102 | 6480464 | Chlorpromazine inhibits the reaction [RANKL protein results in increased expression of CTSK mRNA]; more ... | CTD | PMID:21869564 |
| choline | multiple interactions | ISO | RGD:62102 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CTSK mRNA | CTD | PMID:20938992 |
| clozapine | increases expression | ISO | RGD:61810 | 6480464 | Clozapine results in increased expression of CTSK mRNA | CTD | PMID:16715494 |
| fluoxetine | multiple interactions | ISO | RGD:62102 | 6480464 | Fluoxetine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] | CTD | PMID:15312242 |
| folic acid | multiple interactions | ISO | RGD:62102 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CTSK mRNA | CTD | PMID:20938992 |
| genistein | affects expression | ISO | RGD:62102 | 6480464 | Genistein affects the expression of CTSK mRNA | CTD | PMID:17166402 |
| genistein | decreases expression | ISO | RGD:62102 | 6480464 | Genistein results in decreased expression of CTSK mRNA | CTD | PMID:17295206 |
| genistein | multiple interactions | ISO | RGD:62102 | 6480464 | [CSF1 protein co-treated with TNFSF11 protein co-treated with Genistein] results in decreased expression of CTSK mRNA; more ... | CTD | PMID:17295206 |
| guanethidine | increases expression | ISO | RGD:61810 | 6480464 | Guanethidine results in increased expression of CTSK mRNA | CTD | PMID:14527964 |
| guanethidine | affects expression | ISO | RGD:61810 | 6480464 | Guanethidine affects the expression of CTSK protein | CTD | PMID:14527964 |
| haloperidol | increases expression | ISO | RGD:61810 | 6480464 | Haloperidol results in increased expression of CTSK mRNA | CTD | PMID:16715494 |
| hydralazine | multiple interactions | EXP | | 6480464 | [Hydralazine co-treated with Valproic Acid] results in increased expression of CTSK mRNA | CTD | PMID:17183730 |
| ketamine | increases expression | ISO | RGD:61810 | 6480464 | Ketamine results in increased expression of CTSK mRNA | CTD | PMID:20080153 |
| L-ascorbic acid | increases expression | ISO | RGD:62102 | 6480464 | Ascorbic Acid results in increased expression of CTSK mRNA | CTD | PMID:15730627 |
| L-methionine | multiple interactions | ISO | RGD:62102 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CTSK mRNA | CTD | PMID:20938992 |
| mangiferin | multiple interactions | ISO | RGD:62102 | 6480464 | mangiferin inhibits the reaction [RANKL protein results in increased expression of CTSK mRNA]; more ... | CTD | PMID:20683903 |
| mercaptopurine | increases expression | ISO | RGD:61810 | 6480464 | 6-Mercaptopurine results in increased expression of CTSK mRNA | CTD | PMID:23358152 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:61810 | 6480464 | [Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CTSK mRNA | CTD | PMID:20360939 |
| ozone | multiple interactions | ISO | RGD:62102 | 6480464 | TTPA protein affects the reaction [Ozone results in increased expression of CTSK mRNA] | CTD | PMID:19555225 |
| paclitaxel | increases expression | ISO | RGD:61810 | 6480464 | Paclitaxel results in increased expression of CTSK mRNA; more ... | CTD | PMID:15585946 |
| perfluorooctane-1-sulfonic acid | increases expression | ISO | RGD:61810 | 6480464 | perfluorooctane sulfonic acid results in increased expression of CTSK mRNA | CTD | PMID:22237054 |
| perfluorooctanoic acid | decreases expression | ISO | RGD:61810 | 6480464 | perfluorooctanoic acid results in decreased expression of CTSK mRNA | CTD | PMID:16221955 |
| purine-6-thiol | increases expression | ISO | RGD:61810 | 6480464 | 6-Mercaptopurine results in increased expression of CTSK mRNA | CTD | PMID:23358152 |
| quartz | increases expression | ISO | RGD:61810 | 6480464 | Quartz results in increased expression of CTSK mRNA | CTD | PMID:19836432 |
| quercetin | multiple interactions | ISO | RGD:62102 | 6480464 | Quercetin inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] | CTD | PMID:19495926 |
| raloxifene | affects expression | ISO | RGD:62102 | 6480464 | Raloxifene affects the expression of CTSK mRNA | CTD | PMID:17166402 |
| resveratrol | multiple interactions | EXP | | 6480464 | resveratrol inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CTSK mRNA] | CTD | PMID:16267019 |
| tetradecane | decreases expression | ISO | RGD:61810 | 6480464 | n-tetradecane results in decreased expression of CTSK protein | CTD | PMID:17337753 |
| titanium dioxide | increases expression | ISO | RGD:62102 | 6480464 | titanium dioxide results in increased expression of CTSK mRNA | CTD | PMID:19464567 |
| titanium dioxide | increases expression | ISO | RGD:62102 | 6480464 | titanium dioxide results in increased expression of CTSK mRNA | CTD | PMID:19464567 PMID:21259345 |
| trans-resveratrol | multiple interactions | EXP | | 6480464 | resveratrol inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CTSK mRNA] | CTD | PMID:16267019 |
| tributylstannane | multiple interactions | ISO | RGD:62102 | 6480464 | Tetrachlorodibenzodioxin inhibits the reaction [tributyltin results in decreased expression of CTSK mRNA] | CTD | PMID:22749964 |
| tributylstannane | decreases expression | ISO | RGD:62102 | 6480464 | tributyltin results in decreased expression of CTSK mRNA | CTD | PMID:22749964 |
| valproic acid | multiple interactions | EXP | | 6480464 | [Hydralazine co-treated with Valproic Acid] results in increased expression of CTSK mRNA | CTD | PMID:17183730 |
| zinc atom | decreases activity | ISO | RGD:61810 | 6480464 | Zinc deficiency results in decreased activity of CTSK protein | CTD | PMID:21893222 |
| zinc atom | decreases expression | ISO | RGD:61810 | 6480464 | Zinc deficiency results in decreased expression of CTSK mRNA | CTD | PMID:21893222 |
| zinc sulfate | multiple interactions | ISO | RGD:62102 | 6480464 | [CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] results in decreased expression of CTSK mRNA; more ... | CTD | PMID:17295206 |
| zinc sulfate | decreases expression | ISO | RGD:62102 | 6480464 | Zinc Sulfate results in decreased expression of CTSK mRNA | CTD | PMID:17295206 PMID:18636177 |
| zinc sulfate | multiple interactions | ISO | RGD:62102 | 6480464 | cryptoxanthin promotes the reaction [Zinc Sulfate results in decreased expression of CTSK mRNA]; more ... | CTD | PMID:18636177 |
| zinc(0) | decreases activity | ISO | RGD:61810 | 6480464 | Zinc deficiency results in decreased activity of CTSK protein | CTD | PMID:21893222 |
| zinc(0) | decreases expression | ISO | RGD:61810 | 6480464 | Zinc deficiency results in decreased expression of CTSK mRNA | CTD | PMID:21893222 |